Your browser is no longer supported. Please, upgrade your browser.
IFRX InflaRx N.V. daily Stock Chart
InflaRx N.V.
Index- P/E- EPS (ttm)-740.47 Insider Own8.02% Shs Outstand23.84M Perf Week10.96%
Market Cap760.50M Forward P/E- EPS next Y-0.01 Insider Trans- Shs Float21.54M Perf Month36.15%
Income- PEG- EPS next Q0.00 Inst Own43.10% Short Float0.47% Perf Quarter119.24%
Sales- P/S- EPS this Y-81.80% Inst Trans- Short Ratio1.76 Perf Half Y-
Book/sh-1584.99 P/B- EPS next Y-39.50% ROA- Target Price33.14 Perf Year-
Cash/sh1.16 P/C27.55 EPS next 5Y- ROE- 52W Range14.47 - 34.86 Perf YTD52.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-8.46% Beta-
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low120.53% ATR2.31
Employees17 Current Ratio8.80 Sales Q/Q- Oper. Margin- RSI (14)72.65 Volatility8.59% 8.53%
OptionableNo Debt/Eq- EPS Q/Q-280.20% Profit Margin- Rel Volume0.72 Prev Close31.90
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume58.03K Price31.91
Recom1.80 SMA2024.06% SMA5038.11% SMA20050.62% Volume11,446 Change0.03%
Feb-08-18Initiated B. Riley FBR, Inc. Buy $40
Feb-06-18 07:52AM  InflaRx Announces Appointment of Tony Gibney to Its Board of Directors Business Wire
Feb-01-18 09:55AM  InflaRx Presents at Two Scientific Conferences in February, 2018 Business Wire
Jan-23-18 01:53PM  Breaking Down InflaRx NVs (NASDAQ:IFRX) Ownership Structure Simply Wall St.
Jan-15-18 10:51AM  What Can We Expect for InflaRx NV (NASDAQ:IFRX) Moving Forward? Simply Wall St.
Jan-09-18 08:56AM  InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa Business Wire
Jan-04-18 01:47PM  InflaRx to Present at Upcoming Investor Conferences Business Wire +13.56%
08:00AM  InflaRx NV (NASDAQ:IFRX): Are Analysts Bull Or Bear? Simply Wall St.
Nov-10-17 08:05AM  The Biotech IPO Boom Will Continue, Nasdaq Execs Predict Forbes
Nov-08-17 01:31PM  InflaRX NV (Nasdaq: IFRX) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.